Prescribing cascades

For prescribing clinicians

A prescribing cascade is a drug causing a symptom, the symptom being read as a new condition, and the new condition being treated. Every step is defensible. The result is not.

Why it is invisible

Because nobody makes a mistake. The first prescription was appropriate. The symptom was real. The second prescription was a reasonable response to the symptom presented. The error is not in any decision; it is in the fact that no single person ever saw the sequence.

That is also what makes it findable: read the list in the order it was written. A cascade is a pattern in time, and it disappears in any other sort order.

The shape to look for

1. A new medication appears within weeks to a few months of another one.
2. The problem it treats is a recognized effect of the earlier drug.
3. Nobody recorded whether the earlier drug was reconsidered before the new one was started.

The third item is the diagnostic one. A note saying “reviewed X, symptom persisted, adding Y” is not a cascade. Silence is what makes it one.

Where the anticholinergic version bites

Anticholinergic effects are a fertile source of cascades because they present as ordinary complaints of old age. Constipation, urinary retention, dry mouth, blurred vision, confusion. Each has its own treatment, and several of those treatments are themselves anticholinergic. FDA-approved labeling for a bladder antimuscarinic warns that concomitant anticholinergics “may increase the frequency and/or severity” of dry mouth, constipation and drowsiness, and that anticholinergic effects on gastrointestinal motility may alter the absorption of other drugs.

The burden is a property of the whole list. Treating one anticholinergic effect with another anticholinergic drug is a cascade that also raises the total. Anticholinergic burden.

The sedation cascade

The most consequential version in long-term care does not add a drug. It adds a diagnosis.

A sedating medication is started. The person becomes quieter, slower, less engaged. That is recorded as decline. Decline is attributed to progression of dementia. The care plan adjusts to a person who is now assumed to be further along than they are — fewer activities, less expectation, and less reason to look for a reversible cause. Nothing was prescribed at the last step, and the harm is larger than most prescriptions.

This is why deprescribing is the first step of the framework and assessment the third: you cannot get a baseline through a sedative. Assessment.

The behavior cascade

Its close relative. Untreated pain in someone who cannot report it presents as agitation. Agitation is treated with something sedating. The sedation makes the pain harder to detect and the person harder to assess. The evidence that this loop is real and interruptible is randomized: a cluster randomized trial of 352 nursing home residents with moderate to severe dementia and clinically significant agitation found a stepwise pain-treatment protocol reduced agitation by an average of 17% over eight weeks — and that agitation worsened again after the pain treatment was withdrawn. Pain in residents who cannot tell you.

When the cascade ran the other way

The substitution documented in nursing home co-prescribing is worth reading as a cascade of a different kind. In Ontario nursing homes, among residents dispensed an opioid, concurrent benzodiazepine use fell 53.2% in relative terms between 2009 and 2020 while concurrent gabapentinoid use rose 505.4%. In US nursing homes in 2021, gabapentin was the agent most frequently involved in central nervous system polypharmacy. A class was successfully reduced and the burden reappeared under a different heading. Gabapentinoids.

The practical instruction

Sort the list by start date. For every drug started in the last two years, ask what happened in the eight weeks before it. That is a five-minute exercise and it is the highest-yield thing in this section.

Back to the clinician track.

References

1. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065. PMID 21765198 · DOI 10.1136/bmj.d4065.
2. Hogan DB, Campitelli MA, Bronskill SE, et al. Trends and correlates of concurrent opioid and benzodiazepine and/or gabapentinoid use among Ontario nursing home residents. Journal of the American Geriatrics Society. 2023;71(8):2462–2475. PMID 36942992 · DOI 10.1111/jgs.18320.
3. Jung H, Liu SH, Hume AL, et al. The Prevalence of Central Nervous System-Active Polypharmacy in US Nursing Homes. Journal of the American Medical Directors Association. 2026;27(6):106178. PMID 41895707 · DOI 10.1016/j.jamda.2026.106178.
4. Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Internal Medicine. 2019;179(8):1084–1093. PMID 31233095 · DOI 10.1001/jamainternmed.2019.0677.
5. By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71(7):2052–2081. PMID 37139824 · DOI 10.1111/jgs.18372.

Bibliographic records on this page were retrieved from PubMed. Every reference links to its DOI or PubMed record.

Written and medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, founder and medical director of DWARAA. Last reviewed August 21, 2026. This page is educational. DWARAA does not prescribe, deprescribe, diagnose or treat.